Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors during the central anxious procedure, conolidine modulates alternate molecular targets. A Science Developments research identified that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide ... https://ermaw108wya0.wikijournalist.com/user